FreeStyle Libre Rio
Abbott
What it is
Abbott's first over-the-counter CGM in the US: a no-prescription, 15-day sensor for adults with type 2 diabetes not on insulin. Built on the Libre platform but with no glucose alarms and no AID integration — included here for OTC-category completeness, not as a tool for people living with T1D.
Editorial review: .
Most recent recorded citation date: 2025-04-04. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Accuracy: No Libre Rio-specific pivotal accuracy study has been published. It is built on Abbott's 15-day factory-calibrated Libre platform, whose sensor posted ~8.2% MARD in adults vs YSI — but the Rio is not validated to the iCGM dosing standard the Libre 2 Plus meets, so we score it conservatively pending Rio-specific data.[4]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 70 × 20 + 65 × 15 + 15 × 15 + 85 × 10 + 90 × 10 + 10 × 10 + 70 × 10 + 0 × 5 + 60 × 5 = 5450; divide by total weight 100. Unrounded weighted result: 54.5.
No Libre Rio-specific pivotal accuracy study has been published. It is built on Abbott's 15-day factory-calibrated Libre platform, whose sensor posted ~8.2% MARD in adults vs YSI — but the Rio is not validated to the iCGM dosing standard the Libre 2 Plus meets, so we score it conservatively pending Rio-specific data.[4]
Interstitial lag is comparable to the rest of the Libre line; not a differentiator and not separately characterized for the Rio.[4]
Deliberately closed. The Rio does not drive any automated insulin delivery system, does not integrate with pumps, and is not intended for insulin users — unlike the Libre 2 Plus / 3 Plus, which drive AID. Reads to its own app or reader only.[6]
Up to 15-day wear — among the longest of any CGM (some secondary sources say 14; Abbott's clearance announcement states up to 15 days for Libre systems).[1]
No glucose alarms. The Rio is built for retrospective trend/lifestyle insight, not real-time low/high warnings — a critical limitation that makes it unsuitable for the hypo-detection needs of someone with T1D.[6]
Patch worn on the back of the upper arm; shape, water resistance and Libre 2/3 size comparisons are not verified for the Rio in the sources read.[3]
Glucose only (40-400 mg/dL range); Abbott describes a dual glucose-ketone sensor as in development, so no ketone sensing is credited here.[1]
No prescription needed and priced for consumers, but US-only and indicated only for type-2 non-insulin users — so it is not an access win for people with T1D.[5]
The full picture
The FreeStyle Libre Rio is Abbott's first over-the-counter (OTC) continuous glucose monitor (CGM) in the United States — you can buy it without a prescription. It is a small, factory-calibrated sensor worn on the back of the upper arm that measures glucose in the fluid just under the skin and shows readings on a reader or a compatible smartphone app.1 We include it here for completeness of the OTC CGM category — but read the warnings below: it is not designed for, or indicated for, people with type 1 diabetes.3
Who it's for. The FDA cleared the Libre Rio in June 2024 (510(k) K233861) for adults aged 18 and older with type 2 diabetes who do not use insulin and who typically manage with lifestyle.12 That indication is the whole point of the product, and it excludes T1D.
How it works and accuracy. The Rio is built on Abbott's familiar Libre platform, with no fingerstick calibration.36 Abbott has not published a Rio-specific accuracy study, so any MARD figure for it is an inference. The underlying 15-day Libre sensor posted an overall MARD of about 8.2% in adults (and held up in the low range, with ~97% of results within 15 mg/dL of the lab reference during hypoglycemia) in its pivotal study — but that study validated the prescription Libre 2 Plus / 3 Plus, not the Rio.4 We score the Rio's accuracy conservatively for that reason and flag the gap honestly.
Wear, range, alerts. The sensor is worn for up to 15 days, and its glucose measuring range is 40-400 mg/dL — wide enough to register very low or very high readings, which Abbott highlights as a first for an OTC CGM.1 Critically, the Rio has no glucose alarms: it is built for retrospective trend and lifestyle insight, not for real-time low/high warnings.6 For someone with T1D, the absence of a low-glucose alarm alone makes it the wrong tool.
What it works with. Effectively nothing in the T1D stack. The Rio does not drive any automated insulin delivery (AID) system, does not integrate with pumps, and is not intended for insulin users or DIY loops.6 This is a deliberate, closed consumer design — unlike Abbott's Libre 2 Plus and 3 Plus, which are cleared to power Tandem and Omnipod systems. It has no ketone sensing.1
Access and cost. The Libre Rio is US-only and sold over the counter, so it is paid out of pocket. Abbott's wellness sibling Lingo launched in the US in September 2024 at low-cost consumer pricing, and the Rio was positioned to follow at consumer pricing.5
What's coming. The bigger Abbott story for people with T1D is not the Rio but the iCGM Libre line (Libre 2 Plus / 3 Plus, which drive AID) and the upcoming dual glucose-ketone sensor — both tracked separately on this site. The OTC Rio matters mainly as a sign of where consumer glucose sensing is heading: prescription-free, lifestyle-framed, and aimed at the very large type-2 and wellness market rather than at intensive insulin users.3
Sources
- [1]Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems · Manufacturer · 2024-06-10 — Abbott press release (Jun 10, 2024). Libre Rio = OTC iCGM for non-insulin adults 18+; range 40-400 mg/dL; up to 15-day wear; reader or smartphone app. Lingo (wellness) 14-day wear.
Abbott. Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems (Libre Rio: OTC iCGM, adults 18+ with type 2 not on insulin; range 40-400 mg/dL; up to 15-day wear; reader or smartphone app). PR Newswire / Abbott (June 10, 2024).
- [2]Libre Rio — 510(k) Premarket Notification K233861 · Regulatory decision · 2024-06-07 — FDA 510(k) clearance number K233861 for Libre Rio (Abbott Diabetes Care).
U.S. FDA. Libre Rio — 510(k) Premarket Notification K233861 (Abbott Diabetes Care). FDA 510(k) Database (2024).
- [3]Abbott Launches Lingo & Libre Rio in U.S. Biowearables Market · Manufacturer · 2024-06-25 — Abbott newsroom — strategic positioning; Rio is an OTC iCGM for people with diabetes (type 2, non-insulin).
Abbott. Abbott Launches Lingo & Libre Rio in U.S. Biowearables Market (Libre Rio is an OTC iCGM for people with diabetes — type 2, non-insulin; Lingo is a wellness product). Abbott Newsroom (2024).
- [4]Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design · Peer-reviewed study · 2025-04-04 — Alva S, et al. J Diabetes Sci Technol (2025). doi:10.1177/19322968251329364 (PMID 40183340). Pivotal accuracy of the 15-day Libre platform (8.2% adult MARD); used as the underlying-platform reference — not a Rio-specific study.
Alva S, Bhargava A, Bode B, et al. Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design (8.2% adult MARD; 97% of hypo results within 15 mg/dL; validates the prescription Libre 2 Plus / 3 Plus platform, not the Rio specifically). J Diabetes Sci Technol (2025). doi:10.1177/19322968251329364 (PMID 40183340).
- [5]Abbott debuts Lingo over-the-counter CGM in the US · Science journalism · 2024-09-06 — Lingo launched in the US Sep 2024 at low-cost consumer pricing; Libre Rio (for people with diabetes) to follow. Pricing context for the OTC tier.
Tirrell M. Abbott debuts Lingo over-the-counter CGM in the US (Lingo launched Sept 2024 at low-cost consumer pricing; Libre Rio for people with diabetes to follow at consumer pricing). MedTech Dive (September 2024).
- [6]FDA-Approved Over-the-Counter Libre Rio · Science journalism · 2024-09-01 — Secondary summary — smartphone app, 40-400 mg/dL range, target market adults managing diabetes with lifestyle changes without insulin.
CGM Monitors. FDA-Approved Over-the-Counter Libre Rio — Features and More (no glucose alarms — trend/lifestyle insight only; calibration-free, one-hour warm-up; smartphone app; not for insulin users or AID systems; same small sensor as Libre 2). CGMmonitors.com (2024).